20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Baxter International Inc (NYSE:BAX) posted Q3 revenue of $3.23 billion, in line with the consensus, up 9% on a reported basis, 7% on a constant currency basis, and 6% on an operational basis.
- Adjusted EPS of $1.02 increased 23% and surpassed the estimate of $0.94.
- Growth was led by increased sales in BioPharma Solutions, which benefitted from multiple collaborations to help manufacture COVID-19 vaccines on a contract basis.
- Medication Delivery sales growth advanced low double digits, driven by strength in the U.S. for IV therapies and infusion systems products.
- Clinical Nutrition, Acute Therapies, and Advanced Surgery delivered mid-single-digit growth, driven by ongoing demand, particularly outside the U.S.
- The gross and operating margins remained almost unchanged at 40% and 16%, respectively.
- Outlook: Baxter expects FY21 sales growth of approximately 7% - 8% on a reported basis, 5% - 6% on a constant currency basis, and 4% - 5% on an operational basis.
- It expects an adjusted EPS of $3.58 - $3.62, better than the previous guidance of $3.49 - $3.55, versus the $3.34 consensus.
- For Q4, Baxter expects an adjusted EPS of $1.00 to $1.04, with sales growth of 3% - 4% on a reported basis, 4% - 5% on a constant currency basis and 3% - 4% on an operational basis
- Price Action: BAX shares traded 4.07% lower at $78.72 on the last check Thursday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!